Liver diseases
Alfasigma’s PBC Treatment Ocaliva to Face FDA Advisory Committee in September
Alfasigma, Ocaliva, PBC, FDA advisory committee, primary biliary cholangitis, liver disease treatment
Gilead Sciences Exceeds Q2 Expectations, Boosts Optimism for Seladelpar Decision
Gilead Sciences, Q2 earnings, seladelpar, PBC, liver disease, financial performance, pharmaceuticals
Ipsen and Genfit Secure FDA Approval for Iqirvo, a Breakthrough Treatment for Primary Biliary Cholangitis
Ipsen, Genfit, Iqirvo, FDA approval, primary biliary cholangitis, liver disease, Intercept, Ocaliva
Lilly Touts Fibrosis Win, Strengthens Case for Tirzepatide in MASH Treatment
Eli Lilly, Tirzepatide, MASH, Fibrosis, Liver Disease, Obesity, Diabetes, GLP-1/GIP Dual Agonist
Lilly’s Tirzepatide Demonstrates Efficacy in Mid-Stage MASH Study
Tirzepatide, MASH, Eli Lilly, Fibrosis, Liver Disease, Diabetes, Obesity
Revolutionary Gene Therapy Advancements: Early Trial Results from Leading Biotech Companies
ASGCT24, gene therapy, early trial results, Freeline, Rocket, Creyon, biotech companies, genetic diseases, hemophilia, liver diseases, Parkinson’s disease.